Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03702764
Other study ID # CM0218-GEO
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2019
Est. completion date November 30, 2021

Study information

Verified date July 2021
Source Cardio Med Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of GEOMETRY study is to investigate the correlation between coronary plaque geometric modifications and lesion vulnerability in patients with suspected coronary artery disease referred for cardiac computed tomography angiography (CCTA). Furthermore the study will evaluate the impact of plaque eccentricity and morphology on the rate of major adverse cardiovascular events (MACE) for a 2 years follow-up period.


Description:

Coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. Early detection of CAD may reduce the incidence of myocardial infarction by improving primary prevention and providing more effective treatment methods. A step in this direction is identifying the pattern of coronary plaques which are prone to rupture. Coronary computed tomography angiography (CCTA) has emerged recently as a reliable noninvasive tool used in the evaluation of coronary arteries. Some features related to plaque composition and morphology such as low attenuation plaques, spotty calcification, positive remodeling or napkin ring sign, were already identified as vulnerability markers. However the role of lesion geometry on plaque vulnerability was not investigated yet. This is a prospective, cohort, single-center study which will be carried out in the Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed. The study will include 1.000 subjects with suspected CAD who are referred to CCTA by the attending physician and in which presence of at least one coronary plaque is confirmed by CCTA. Plaque burden, composition, and morphology will be assessed for each plaque. Longitudinal and transversal eccentricity will be also assessed in each plaque and in all cases, eccentricity index will be calculated in cross-section plane at the degree of maximum stenosis in order to determine the position of the remaining circulant lumen and to classify the plaque into concentric and eccentric lesion. The study will be conducted over a period of 3 years, in which patients will be examined at baseline, and will be followed-up for 2 years for occurrence of MACE. Study objectives: Primary: to evaluate the association between different patterns of plaque geometry and the risk for major adverse cardiac events MACE (all-cause mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated hospitalizations for cardiovascular related incidents, cerebrovascular events) during a 2-year follow-up, Secondary: to evaluate the association of plaque eccentricity, plaque vulnerability and plaque progression after 2 years of follow-up Study Timeline: - Baseline (day 0) - Obtain and document consent from participant on study consent form. - Verify inclusion/exclusion criteria. - Obtain demographic information, medical history, medication history, alcohol and tobacco use history. - Record results of physical examinations and 12-lead ECG. - Collect blood specimens. - Imaging: 128-multislice CT angiography. - Visit 1 (month 6) - Record results of physical examinations, 12-lead ECG and medical history. - MACE assessment - Visit 2 (month 12) - Record results of physical examinations, 12-lead ECG and medical history. - MACE assessment - Visit 3 (month 18) - Record results of physical examinations, 12-lead ECG and medical history. - MACE assessment - Final study visit (month 24) - Record results of physical examinations, 12-lead ECG and medical history. - Repeat CCTA and plaque assessment - End-point evaluation. Study procedures: - Medical history, clinical examination, laboratory tests; - 12-lead ECG - 128-multislice CT coronary angiography with the evaluation of: calcium score, plaque burden, markers for lesion severity (degree of stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness); morphological plaque characteristics (plaque related volumes, plaque burden, remodeling indexes); shear stress by computational fluid dynamics; markers of plaque vulnerability (low attenuation plaque, spotty calcification, positive remodeling, napkin ring sign); plaque geometry by eccentricity index, longitudinal and transversal eccentricity.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date November 30, 2021
Est. primary completion date November 30, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with suspected coronary artery disease (CAD) and pre-test probability of CAD between 15% and 85%, who undergo CCTA, and in whom CCTA has identified presence of at least one coronary plaque - Ability to provide informed consent - Age grater then 18 years Exclusion Criteria: - Patients with pre-test probability of CAD >85% or <15% - Electrocardiographic evidence of STEMI - Presence of pre-existing CAD including prior myocardial infarction - History of coronary artery revascularization (by percutaneous coronary intervention, stent or bypass graft surgery) - Atrial fibrillation or other irregular rhythm - Unwillingness or incapacity to provide informed consent - Allergy to iodine contrast media - Inability to tolerate beta-blocker medication - Renal insufficiency (creatinine greater than 1.5 mg/dL) or renal failure requiring dialysis - Pregnant women or lactation - Active malignancy or malignancy within the last 5 year prior to enrolment - Conditions associated with an estimated life expectancy of under 2 years - Coronary calcium score >1000

Study Design


Intervention

Diagnostic Test:
CCTA
128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.

Locations

Country Name City State
Romania Cardio Med Medical Center Târgu-Mures Mures

Sponsors (3)

Lead Sponsor Collaborator
Cardio Med Medical Center University Hospital of Targu Mures, Romania, University of Targu Mures, Romania

Country where clinical trial is conducted

Romania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major adverse cardiovascular events Incidence of MACE during follow-up Month 24
Secondary Coronary plaque vulnerability associated to plaque eccentricity Number of vulnerability markers in eccentric vs concentric plaques Month 24
See also
  Status Clinical Trial Phase
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study